We observed that high-CAF-risk group LBC patients were less sensitive to several drugs, including docetaxel, which is consistent with the finding that up-regulation of THBS1 following neoadjuvant chemotherapy containing docetaxel was associated with docetaxel chemotherapy resistance in breast cancer patients (71). This evidence concerns the gene THBS1 and CDH1-related diffuse gastric and lobular breast cancer syndrome.